Simvastatin‐Mediated Molecular Mechanisms Underlying the Growth Inhibition of Testicular Leydig Tumour Cells
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70786 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Arianna De Luca und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, Rende, Cosenza, Italy. Hauptthemen laut MEDLINE: Simvastatin, Testicular Neoplasms, Leydig Cell Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Calabria (ex 60%), Università della Calabria.
Abstract (Originalsprache)
Leydig cell tumours (LCTs) are uncommon stromal neoplasms of the testis, accounting for less than 3% of all gonadal cancers. Most of them are benign, but the malignant ones are very aggressive without specific effective treatment. Several studies reported pharmacologic insight into the use of statins as anti‐tumour agents, but their efficacy on LCTs has not been investigated. Previously, we emphasised the central role of insulin‐like growth factor 1 (IGF1)/insulin‐like growth factor 1 receptor (IGF1R) signalling in Leydig cell tumorigenesis; here, we showed that simvastatin reduces cell proliferation, determines cell cycle arrest at the G1 phase, and induces reactive oxygen species (ROS) accumulation and apoptosis in R2C and LC540 rat Leydig tumour cells. Furthermore, it prevents isoprenoid farnesyl pyrophosphate (FPP) formation and decreases IGF1R expression, leading to the breakdown of the IGF1R signalling pathway. Importantly, we observed that simvastatin synergised with cisplatin in reducing tumour cell proliferation. Collectively, these data suggest that simvastatin is a potential anticancer drug capable of counteracting LCT growth, and it could be proposed as an adjuvant for chemotherapy in LCT treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, Rende, Cosenza, Italy.
- Department of Health Sciences, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
ORCID-Profile: Vincenzo Pezzi, Adele Chimento
Förderung
- University of Calabria (ex 60%)
- Università della Calabria
Zitieren
APA
De Luca, A., Zavaglia, L., Vuono, L. F., Giordano, F., La Padula, D., De Amicis, F., Pezzi, V., & Chimento, A. (2025). Simvastatin‐Mediated Molecular Mechanisms Underlying the Growth Inhibition of Testicular Leydig Tumour Cells. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70786
Vancouver
De Luca A, Zavaglia L, Vuono LF, Giordano F, La Padula D, De Amicis F, et al. Simvastatin‐Mediated Molecular Mechanisms Underlying the Growth Inhibition of Testicular Leydig Tumour Cells. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70786
BibTeX
@article{DeLuca2025,
author = {De Luca, Arianna and Zavaglia, Lucia and Vuono, Lucia Francesca and Giordano, Francesca and La Padula, Davide and De Amicis, Francesca and Pezzi, Vincenzo and Chimento, Adele},
title = {Simvastatin‐Mediated Molecular Mechanisms Underlying the Growth Inhibition of Testicular Leydig Tumour Cells},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70786}
}
EUVIMED